<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AF8FD2D5-1492-4026-BDAB-332A0883A75F"><gtr:id>AF8FD2D5-1492-4026-BDAB-332A0883A75F</gtr:id><gtr:name>Hammersmith Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/98B6C281-02AB-4084-BD54-ECD2D6CE6DA6"><gtr:id>98B6C281-02AB-4084-BD54-ECD2D6CE6DA6</gtr:id><gtr:name>Innovata Ltd (formerly ML Laboratories)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AF8FD2D5-1492-4026-BDAB-332A0883A75F"><gtr:id>AF8FD2D5-1492-4026-BDAB-332A0883A75F</gtr:id><gtr:name>Hammersmith Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/98B6C281-02AB-4084-BD54-ECD2D6CE6DA6"><gtr:id>98B6C281-02AB-4084-BD54-ECD2D6CE6DA6</gtr:id><gtr:name>Innovata Ltd (formerly ML Laboratories)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DC2ACC5E-A685-4B82-B718-3DED8E92FDC7"><gtr:id>DC2ACC5E-A685-4B82-B718-3DED8E92FDC7</gtr:id><gtr:firstName>Michelle</gtr:firstName><gtr:surname>Lockley</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6553"><gtr:id>45F6FFDD-17D4-4B3C-ABAB-DC46181AAADC</gtr:id><gtr:title>Use Of A Novel Replicating Adenovirus, dl922-947, In Ovarian Carcinoma.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6553</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>181132</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hammersmith Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Eric Aboagye</gtr:description><gtr:id>CBC7AE2E-66B0-474D-9658-2B7C2DBA6694</gtr:id><gtr:impact>paper by Leyton, Lockley et al</gtr:impact><gtr:outcomeId>gkbCUxeJhGQ-1</gtr:outcomeId><gtr:partnerContribution>lead to publication by Leyton, Lockely et al</gtr:partnerContribution><gtr:piContribution>collaborated on paper by Leyton, Lockley et al</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts and The London School of Medicine and Dentistry</gtr:department><gtr:description>Prof Fran Balkwill</gtr:description><gtr:id>B3848D2C-372A-4565-9107-F74B2B45A417</gtr:id><gtr:impact>publication by salako et al. and to subsequent publications since completion of MRC fellowship. She is a collaborator on my current CRUK clinician scientist fellowship</gtr:impact><gtr:outcomeId>g1rQCHpPw1S-1</gtr:outcomeId><gtr:partnerContribution>collaborated on work with viruses and inflammatory cytokines and leading to publications</gtr:partnerContribution><gtr:piContribution>collaborated on work with iflammatory cytokines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Innovata Ltd (formerly ML Laboratories)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Innovata collaboration</gtr:description><gtr:id>473CC4D5-4697-4229-80CD-02EC6420E3FE</gtr:id><gtr:impact>used icodextrin for in vivo delivery of intraperitoneal viruses, therefore used in all of the listed publications</gtr:impact><gtr:outcomeId>UaEnUAaWZKf-1</gtr:outcomeId><gtr:partnerContribution>Icodextrin was obtained from Innovata (previously ML laboratories) for use as a vehicle for the intraperitoneal delivery of dl922-947</gtr:partnerContribution><gtr:piContribution>NA</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>852327</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research Uk Clinician Scientist Fellowship</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>3D3AC34C-2494-421F-847D-E4D5888DA1B3</gtr:id><gtr:outcomeId>Gqwx93nG8h10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7EFC70D6-D841-44B2-9DF7-AEDB0B7685F9</gtr:id><gtr:title>p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ae38f4230ee7fff590c132d18ee916f"><gtr:id>7ae38f4230ee7fff590c132d18ee916f</gtr:id><gtr:otherNames>Flak MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>pm_17294_24_20598155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68D07DAE-EC3F-441F-8A98-489F8A76F08A</gtr:id><gtr:title>Inhibition of the inflammatory cytokine TNF-a increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a468e59184e25256296033a3033450c2"><gtr:id>a468e59184e25256296033a3033450c2</gtr:id><gtr:otherNames>Salako MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>Vh9yy5T3kpr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE647B18-C9BA-491D-AE4E-98432379CF54</gtr:id><gtr:title>Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a460ccf3c8751ea105f1d5a53e60a84"><gtr:id>5a460ccf3c8751ea105f1d5a53e60a84</gtr:id><gtr:otherNames>Baird SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>LXxsptHpwFc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>028F965C-80DD-4F8A-B916-52D4E9F825DD</gtr:id><gtr:title>Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis.</gtr:title><gtr:parentPublicationTitle>Experimental cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47021f183ffb28ee647717b052819372"><gtr:id>47021f183ffb28ee647717b052819372</gtr:id><gtr:otherNames>McNeish IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0014-4827</gtr:issn><gtr:outcomeId>56b878d902c701.45181359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B44D111-F463-4818-A2A4-C38F089478FE</gtr:id><gtr:title>Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd56b27499dc6ac5cd814c6124341426"><gtr:id>cd56b27499dc6ac5cd814c6124341426</gtr:id><gtr:otherNames>Lockley M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>JDtMzp8JAhz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4D29FF8-0AA7-4A86-BAFC-F75CDA7EF9F4</gtr:id><gtr:title>Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d632792a68822ae75e4563d1222704e"><gtr:id>5d632792a68822ae75e4563d1222704e</gtr:id><gtr:otherNames>Leyton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>CgRnFWVRqTQ</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6553</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>